Linthicum, MD, May 14, 2014—The American Urological Association (AUA) today announced amendments to its 2013 Castration Resistant Prostate Cancer (CRPC) guideline. These amendments were made as part of the AUA’s update literature review (ULR) process, whereby an additional systematic review is conducted to maintain guideline currency with newly published relevant literature.
New guideline statements added to the Castration Resistant Prostate Cancer guideline include:
- Clinicians should offer radium-223 to patients with symptomatic, metastatic CRPC (mCRPC) with good performance status and no prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease (Standard; Evidence Level Grade B).
- Clinicians may offer radium-223 to patients with symptomatic mCRPC with poor performance status and no prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease in select casts, specifically when the performance status is directly related to symptoms related to bone metastases (Expert Opinion).
- Clinicians should offer radium-223 to patients with good performance status who received prior docetaxel chemotherapy with symptomatic bone metastases and without known visceral disease (Standard; Evidence Level Grade B).
The full CRPC guideline, including new amendments, is available here: www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm.
All AUA clinical practice guidance documents, including guidelines, best practices and white papers, are available online at www.AUAnet.org.
NOTE TO REPORTERS: Expert spokespeople are available to discuss these Guidelines. Please contact the Communications Office at 410-689-3932 for more information or to arrange an interview.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 20,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Christine Frey, AUA